Journal article
Overall survival with palbociclib and fulvestrant in advanced breast cancer
NC Turner, DJ Slamon, J Ro, I Bondarenko, SA Im, N Masuda, M Colleoni, A DeMichele, S Loi, S Verma, H Iwata, N Harbeck, S Loibl, F André, KP Theall, X Huang, C Giorgetti, CH Bartlett, M Cristofanilli
New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2018
Abstract
BACKGROUND: The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We report the results of a prespecified analysis of overall survival. METHODS: We randomly assigned patients with hormone-receptor-positive, HER2-negative advanced breast cancer who had progression or relapse during previous endocrine therapy to receive palbociclib plus fulvestrant or placebo plus fulvestrant. We analyzed overall survival; the effect of palbociclib according to the prespecified stratification fac..
View full abstractGrants
Funding Acknowledgements
Supported by Pfizer.